ARTICLE | Company News
Portola: FDA won't require betrixaban meeting
February 8, 2017 4:24 PM UTC
Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said FDA does not plan to hold an advisory committee meeting to discuss an NDA for the company's betrixaban (PRT054021). The agency did not identify any issues during its mid-cycle review that require a meeting, Portola said.
Betrixaban is under Priority Review for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. Its PDUFA date is June 24 (see BioCentury Extra, Dec. 23, 2016)...
BCIQ Company Profiles
BCIQ Target Profiles